<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
September 26, 2000
----------------------------
(Date of Earliest Event Reported)
BioTransplant Incorporated
-------------------------------------------------------------------------------
(Exact name of Registrant as Specified in its Charter)
DELAWARE 0-28324 04-3119555
---------------------------- -------------------- ------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
Building 75, Third Avenue, Charlestown Navy Yard, Charlestown, MA 02129
-------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (617) 241-5200
-------------------------------------------------------------------------------
(Former Name or Former Address if Changed Since Last Report)
<PAGE>
ITEM 5: OTHER EVENTS
On September 26, 2000, BioTransplant Incorporated issued a press
release announcing that it had entered into an arrangement with Novartis Pharma
AG to combine their respective expertise in the field of xenotransplantation
into a new independent company. A copy of the press release is attached hereto
as Exhibit 99.1. See "Item 7 - Financial Statements and Exhibits."
ITEM 7: FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
Exhibit 99.1 -- Press Release dated September 26, 2000
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
October 10, 2000 BIOTRANSPLANT INCORPORATED
/s/ Richard V. Capasso
---------------------------------------
Richard V. Capasso
Vice President of Finance & Treasurer
<PAGE>
EXHIBIT INDEX
NUMBER DESCRIPTION
99.1 Press release dated September 26 , 2000
